Journal
ADVANCES IN ANATOMIC PATHOLOGY
Volume 24, Issue 5, Pages 235-251Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PAP.0000000000000162
Keywords
lymphocytes; tumor-infiltrating; biomarkers; cancer; immunotherapy; pathology
Categories
Funding
- Breast Cancer Research Foundation (BRCF)
- ISCiii/FEDER (CIBERONCO) [PI15/00934]
- NIH (NCI) [K23 CA204726]
- National Breast Cancer Foundation [PRAC-16-006] Funding Source: researchfish
Ask authors/readers for more resources
Assessment of tumor-infiltrating lymphocytes (TILs) in histopathologic specimens can provide important prognostic information in diverse solid tumor types, and may also be of value in predicting response to treatments. However, implementation as a routine clinical biomarker has not yet been achieved. As successful use of immune checkpoint inhibitors and other forms of immunotherapy become a clinical reality, the need for widely applicable, accessible, and reliable immunooncology biomarkers is clear. In part 1 of this review we briefly discuss the host immune response to tumors and different approaches to TIL assessment. We propose a standardized methodology to assess TILs in solid tumors on hematoxylin and eosin sections, in both primary and metastatic settings, based on the International Immuno-Oncology Biomarker Working Group guidelines for TIL assessment in invasive breast carcinoma. A review of the literature regarding the value of TIL assessment in different solid tumor types follows in part 2. The method we propose is reproducible, affordable, easily applied, and has demonstrated prognostic and predictive significance in invasive breast carcinoma. This standardized methodology may be used as a reference against which other methods are compared, and should be evaluated for clinical validity and utility. Standardization of TIL assessment will help to improve consistency and reproducibility in this field, enrich both the quality and quantity of comparable evidence, and help to thoroughly evaluate the utility of TILs assessment in this era of immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available